Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country
Leukemia Research Reports · 2026 · 25 · 100565
DOI: 10.1016/j.lrr.2026.100565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia Research Reports, 2026. Verfasst von Ha Thanh Nguyen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemotherapy, National Institute of Hematology and Blood Transfusion, Hanoi, Vietnam. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hypomethylating agents such as decitabine represent a key treatment option for elderly acute myeloid leukemia (AML) patients who are unfit for intensive chemotherapy. However, real-world evidence from low- and middle-income countries (LMICs), including Vietnam, remains scarce. This study aimed to identify baseline clinical and laboratory predictors of 1-year overall survival (OS) in elderly Vietnamese AML patients treated with decitabine.
Methods
This prospective, single-center, observational study was conducted at the National Institute of Hematology and Blood Transfusion, Vietnam, from April 2023 to June 2025. Seventy newly diagnosed AML patients aged ≥ 60 years received decitabine. The primary outcome was 1-year OS. Baseline demographic, clinical, hematologic, and immunophenotypic variables were analyzed using univariate and multivariate Cox regression. Treatment response was descriptively evaluated in patients completing ≥4 cycles.
Results
The 1-year OS rate was 38.6 %, with a median survival of 276.0 days. Elevated bone marrow cell count (HR: 1.003, p = 0.002), fibrinogen (HR: 1.22, p = 0.044), and urea (HR: 1.23, p = 0.001) were independently associated with increased mortality. CD64 positivity (HR: 0.29, p = 0.029) and urban residence (HR: 0.43, p = 0.014) were protective. Among 39 patients completing ≥4 cycles, 48.7 % achieved a complete response. No significant survival difference was observed between responders and non-responders.
Conclusion
This first prospective real-world study in Vietnam identified accessible predictors of survival in elderly AML patients receiving decitabine. The findings may aid early risk stratification using simple baseline parameters in LMIC settings, where access to molecular diagnostics may be limited, and warrant multicenter validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemotherapy, National Institute of Hematology and Blood Transfusion, Hanoi, Vietnam.
- Department of Hematology and Blood transfusion, Hanoi Medical University, Hanoi, Vietnam.
- Department of Life Sciences, University of Science and Technology of Hanoi, Vietnam Academy of Science and Technology, Hanoi, Vietnam.
Zitieren
APA
Nguyen, H. T., Bach, Q. K., Nguyen, Q. N., Nguyen, V. N., Nguyen, T. V. A., & Pham-The, H. (2026). Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country. Leukemia Research Reports, 25, 100565. https://doi.org/10.1016/j.lrr.2026.100565
Vancouver
Nguyen HT, Bach QK, Nguyen QN, Nguyen VN, Nguyen TVA, Pham-The H. Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country. Leukemia Research Reports. 2026;25:100565. doi:10.1016/j.lrr.2026.100565
BibTeX
@article{Nguyen2026,
author = {Nguyen, Ha Thanh and Bach, Quoc Khanh and Nguyen, Quoc Nhat and Nguyen, Van Nam and Nguyen, Thi Van Anh and Pham-The, Hai},
title = {Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country},
journal = {Leukemia Research Reports},
year = {2026},
volume = {25},
pages = {100565},
doi = {10.1016/j.lrr.2026.100565}
}
EUVIMED